)

Addex Therapeutics (ADXN) investor relations material
Addex Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Significant progress in GABA B PAM program with IND enabling studies completed for substance use disorders in partnership with Indivior; company eligible for milestone payments and royalties.
Regained rights to mGluR2 positive allosteric modulator program from Johnson & Johnson and evaluating new indications.
Repositioned diproglurant (mGluR5 negative modulator) for brain injury recovery, secured option for exclusive IP license, and announced collaboration with Sinntaxis AB in April 2025.
Invested in Stellicla, a company with a precision medicine platform for neurodevelopmental disorders, supporting broader application in heterogeneous patient populations.
Divested allosteric modulator discovery platform and preclinical programs to Neurosterix Pharma Sàrl in April 2024, receiving CHF 5.0 million and a 20% equity interest in Neurosterix US Holdings LLC.
Financial highlights
Ended H1 2025 with CHF 2.3 million in cash, providing runway through mid-2026.
Net loss for H1 2025 was CHF 3.3 million, compared to a net profit of CHF 9.8 million in H1 2024, which included a one-time gain from the Neurosterix Transaction.
Revenue for H1 2025 was CHF 0.35 million, down from CHF 0.65 million in the prior year, due to completion of the Indivior research phase.
R&D expenses for Q2 2025 were $200,000, down $100,000 year-over-year, mainly due to the end of the Indivior research phase.
Share of net loss from Neurosterix was CHF 2.1 million for H1 2025.
Outlook and guidance
Cash position does not fund unpartnered programs into the clinic; additional financing required.
IND enabling studies for independent GABA B PAM program for chronic cough ready to start, pending financing.
Expenses expected to increase as GABA B PAM for chronic cough advances and further clinical trials are initiated.
Management continues to seek additional funding through equity, collaborations, or licensing.
Stellicla pursuing Series C financing and exploring public listing options.
Next Addex Therapeutics earnings date

Next Addex Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage